A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)

Justin M Watts; Maria R Baer; Sangmin Lee; Jay Yang; Shira Naomi Dinner; Thomas Prebet; Gary J Schiller; Karen Seiter; Paul Brent Ferrell; Patrick Francis Kelly; Ping Li; Jennifer Sweeney; Courtney Watson; Hesham Mohamed; Jorge E Cortes

doi:10.1200/JCO.2018.36.15_suppl.7009

Back

A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)

Journal article

Peer reviewed

A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)

Justin M Watts, Maria R Baer, Sangmin Lee, Jay Yang, Shira Naomi Dinner, Thomas Prebet, Gary J Schiller, Karen Seiter, Paul Brent Ferrell, Patrick Francis Kelly, …

Journal of clinical oncology, Vol.36(15_suppl), pp.7009-7009

2018-05-20

DOI: https://doi.org/10.1200/JCO.2018.36.15_suppl.7009

Metrics

7 Record Views

17 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.103 Blood Disorders; 1.103.155 Acute Myeloid Leukemia
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
Creators: Justin M Watts - Memorial Sloan Kettering Cancer Center, New York, NY
Maria R Baer - University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC), Baltimore, MD
Sangmin Lee - Columbia Univ, New York, NY
Jay Yang - Karmanos Cancer Institute, Detroit, MI
Shira Naomi Dinner - Northwestern Memorial Hospital, Chicago, IL
Thomas Prebet - Yale School of Medicine, New Haven, CT
Gary J Schiller - University of California, Los Angeles, Los Angeles, CA
Karen Seiter - New York Medical College, Valhalla, NY
Paul Brent Ferrell - Vanderbilt University School of Medicine, Nashville, TN
Patrick Francis Kelly - FORMA Therapeutics, Inc., Watertown, MA
Ping Li - FORMA Therapeutics, Inc., Watertown, MA
Jennifer Sweeney - FORMA Therapeutics, Inc., Watertown, MA
Courtney Watson - FORMA Therapeutics, Inc., Watertown, MA
Hesham Mohamed - FORMA Therapeutics, Inc., Watertown, MA
Jorge E Cortes - The University of Texas MD Anderson Cancer Center, Houston, TX
Publication Details: Journal of clinical oncology, Vol.36(15_suppl), pp.7009-7009
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031598084302976